Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 40, pages 1007–1017 (2007)Cite this article

Abstract

Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pre-transplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on 90Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose 90Y-ibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose 90Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also 90Y-ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006; 12: 1–30.

    Article  CAS  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  3. Ladetto M, Ricca I, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: results from a multicenter randomized GITMO trial. Blood 2005; 106, abstract 675.

  4. Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben Bassat I et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457–464.

    Article  CAS  Google Scholar 

  5. Bitran JD, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383–388.

    Article  Google Scholar 

  6. Villela L, Sureda A, Canals C, Sanz Jr MA, Martino R, Valcarcel D et al. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica 2003; 88: 300–305.

    PubMed  Google Scholar 

  7. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 37: 1017–1022.

    Article  CAS  Google Scholar 

  8. Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593–599.

    Article  CAS  Google Scholar 

  9. Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 2005; 46: 1575–1579.

    Article  CAS  Google Scholar 

  10. Khouri IF . Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006, 390–397.

    Article  Google Scholar 

  11. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  Google Scholar 

  12. Bierman PJ, Sweetenham JW, Loberiza Jr FR, Taghipour G, Lazarus HM, Rizzo JD et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation—The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744–3753.

    Article  Google Scholar 

  13. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003; 14: 737–744.

    Article  CAS  Google Scholar 

  14. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R . Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021–1028.

    Article  CAS  Google Scholar 

  15. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; e-pub ahead of print, 26 June 2007.

  16. Smith SM . Reduced-intensity transplantation for lymphoma. Curr Treat Options Oncol 2006; 7: 295–305.

    Article  Google Scholar 

  17. Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 92: 627–634.

    Article  Google Scholar 

  18. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24: 4150–4157.

    Article  Google Scholar 

  19. Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K . Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymphoma 2006; 47: 967–977.

    Article  CAS  Google Scholar 

  20. Hagenbeek A, Lewington V . Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005; 16: 786–792.

    Article  CAS  Google Scholar 

  21. Weigert O, Illidge T, Hiddemann W, Dreyling M . Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006; 107: 686–695.

    Article  CAS  Google Scholar 

  22. Witzig TE . Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol 2006; 19: 655–668.

    Article  CAS  Google Scholar 

  23. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263–1270.

    Article  CAS  Google Scholar 

  24. Shimoni A, Zwass T, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Yttrium-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem-cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007; 35: 534–540.

    Article  CAS  Google Scholar 

  25. Krishnan AY, Nademanee A, Forman SJ, Fung H, Molina A, Yamauchi D et al. The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non Hodgkin's lymphoma (NHL). J Clin Oncol 2005; ASCO Annual Meeting Proceedings 23[16S], abstract 6566.

  26. Krishnan A, Raubitschek A, Forman SJ, Fung H, Molina A, Yamauchi D et al. New transplant strategies utilizing radioimmunotherapy (RIT) based regimens to reduce relapse in high risk mantle cell lymphoma (MCL). Blood 2005; 106, abstract 681.

  27. Krishnan AK, Raubitschek AR, Forman S, Fung HF, Molina AM, Yamauchi DY et al. Transplant regimens for high-risk mantle cell lymphoma: the effect of incorporating ibritumomab tiuxetan radioimmunotherapy on relapse rate. Haematologica 2006; 91 (Suppl 1), abstract 0209.

  28. Krishnan AY, Nademanee A, Raubitschek A, Fung HC, Molina A, Yamauchi D et al. A comparison of BEAM and yttrium 90 ibritumomab tiuxetan (Zevalin) in addition to BEAM (Z-BEAM) in older patients undergoing autologous stem cell transplant (ASCT) for B-cell lymphomas: impact of radioimmunotherapy on transplant outcomes. Blood 2006; 108, abstract 3043.

  29. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L et al. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). Blood 2006; 108, abstract 315.

  30. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467.

    Article  CAS  Google Scholar 

  31. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 181–194.

    Article  CAS  Google Scholar 

  32. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896–2902.

    Article  CAS  Google Scholar 

  33. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Y ibritumomab tiuxetan (Zevalin®; 90YZ) doses higher than 0.4 mCi/kg may be safely combined with high-dose BEAM and autotransplant: the role for dosimetry. Blood 2004; 104, abstract 1162.

  34. Winter J, Inwards D, Spies S, Wiseman G, Patton D, Erwin W et al. Zevalin (90YZ) doses >0.5 mCi/kg may be combined with high-dose BEAM and autotransplant (ASCT). ICML 2005 Proceedings; Ann Oncol 16: V95–V104 (abstract 215).

  35. Winter JN, Inwards D, Spies S, Wiseman G, Patton D, Erwin W et al. Y ibritumomab tiuxetan (Zevalin; 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. Blood 2006; 108, abstract 330.

  36. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934–2942.

    CAS  PubMed  Google Scholar 

  37. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158–3162.

    Article  CAS  Google Scholar 

  38. Devizzi L, Seregni E, Guidetti A, Forni C, Coliva A, Magni M et al. High-dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has minimal toxicity and full feasibility in an outpatient setting. Blood 2005; 106, abstract 2737.

  39. Devizzi L, Seregni E, Guidetti A, Forni C, Coliva A, Magni M et al. High-dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has promising activity, minimal toxicity and full feasibility in an outpatient setting. Blood 2006; 108, abstract 3047.

  40. Vanazzi A, Ferrucci PF, Ferrari M, Calabrese L, Cremonesi M, Bartolomei M et al. High dose Zevalin (90Yttrium ibritumomab tiuxetan) treatment with PBSC support in refractory-resistant NHL patients: preliminary results of a phase I/II study. Blood 2005; 106, abstract 488.

  41. Vanazzi A, Ferrucci PF, Grana C, Cremonesi M, Clerici M, Radice D et al. High dose 90Yttrium ibritumomab tiuxetan (Zevalin) with PBSC support in refractory-resistant NHL patients: a phase I/II study. Blood 2006; 108, abstract 2720.

  42. Vanazzi A, Ferrucci P, Grana C, Cremonesi M, Chinol M, Papi S et al. High dose 90Yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: preliminary results of a phase I/II study. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I. 24[18S], abstract 7587.

  43. Flinn I . Dose finding trial of yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I 24[18S], abstract 7535.

  44. Flinn IW, Kahl BS, Frey E, Bianco JA, Hammes RJ, Billing LS et al. Dose finding trial of yttrium 90 (90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 2004; 104, abstract 897.

  45. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–1224.

    Article  CAS  Google Scholar 

  46. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336–340.

    Article  CAS  Google Scholar 

  47. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270–3278.

    Article  CAS  Google Scholar 

  48. Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002; 94: 1363–1372.

    Article  CAS  Google Scholar 

  49. Hohloch K, Wulf G, Jung W, Stitz E, Meller J, Glass B et al. Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: results of a phase II study of the German RAIT study group. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I 24, abstract 13007.

  50. Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or =60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25: 1396–1402.

    Article  Google Scholar 

  51. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S . Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897–906.

    Article  Google Scholar 

  52. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S et al. Analysis of the incidence of treatment-related myelodysplastic syndrome and acute myelogenous leukaemia in registration and compassionate-use trials of ibritumomab tiuxetan radioimmunotherapy (RIT). Blood 2006; 180, abstract 485.

  53. Otte A, Dierckx RA . Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk? Nucl Med Commun 2005; 26: 1045–1047.

    Article  Google Scholar 

  54. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005; 105: 4576–4582.

    Article  CAS  Google Scholar 

  55. Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O et al. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006; 47: 59–63.

    Article  CAS  Google Scholar 

  56. Shimoni A, Zwas T, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin's lymphoma. Blood 2005; 106, abstract 1131.

  57. Shimoni A, Zwas T, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Ibritumomab tiuxetan (Zevalin®) combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with chemo-refractory non-Hodgkin lymphoma. Bone Marrow Transplant 2007; 39 (Suppl 1s), abstract P511.

  58. Gopal AK, Rajendran JG, Pagel JP, Guthrie KA, Maloney DG, Appelbaum FR et al. A phase II trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20+ B-cell non-Hodgkin's lymphoma (NHL). Blood 2006; 108, abstract 316.

Download references

Acknowledgements

The 90Y-ibritumomab tiuxetan transplantation workshop (November 2006, Paris, France) was supported by Bayer Schering Pharma AG, Berlin, Germany. The workshop was chaired by Christian Gisselbrecht (France). Participants were Wolfgang Bethge (Germany), Rafael F Duarte (Spain), Bertram Glass (Germany), Corinne Haioun (France), Giovanni Martinelli (Italy), Arnon Nagler (Israel), Ruth Pettengell (UK), Anna Sureda (Spain), Hervé Tilly (France) and Keith Wilson (UK). Alessandro M Gianni (Italy) also contributed to this article.

Author information

Authors and Affiliations

  1. Institut d'Hématologie, Hôpital Saint-Louis, Paris, France

    C Gisselbrecht

  2. Medizinische Universitätsklinik II Hematology/Oncology, Tübingen, Germany

    W Bethge

  3. Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain

    R F Duarte

  4. Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

    A M Gianni

  5. University Hospital Göttingen, Göttingen, Germany

    B Glass

  6. Service d'Hématologie Clinique, Hôpital Henri Mondor, Créteil, France

    C Haioun

  7. European Institute of Oncology, Milan, Italy

    G Martinelli

  8. Chaim Sheba Medical Center, Tel-Hashomer, Israel

    A Nagler

  9. St George's Hospital, University of London, London, UK

    R Pettengell

  10. Hospital de la Santa Creu i Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Spain

    A Sureda

  11. Department of Hematology, Centre Henri Becquerel, Rouen, France

    H Tilly

  12. School of Medicine, Cardiff University, Wales, UK

    K Wilson

Authors
  1. C Gisselbrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Bethge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R F Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A M Gianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Glass
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Haioun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Martinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Pettengell
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Tilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Gisselbrecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gisselbrecht, C., Bethge, W., Duarte, R. et al. Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 40, 1007–1017 (2007). https://doi.org/10.1038/sj.bmt.1705868

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705868

Keywords

This article is cited by

Search

Advanced search

Quick links